Default company panoramic image
C7016576 73b8 4893 9914 2fa068a93ed1

XPD Holdings, LLC

XPD Holdings is an innovative biotechnology company developing a portfolio of novel multifuntional antioxidants for multiple indications.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Ann Arbor, MI, USA
  • Currency USD
  • Founded October 2011
  • Employees 7

Company Summary

XPD Holdings LLC is an innovative developer of pharmaceuticals designed to address disorders that have inflammation as a core pathology. Our experienced drug development team has designed a robust portfolio of novel, multifunctional antioxidant molecules with potential for treating patients afflicted with a wide range of debilitating CNS, CV, pulmonary, musculoskeletal and systemic diseases. Lead compound screning in neuroprotection is ongoing.


  • Default avatar
    Steven K. Duddy
    Chief Scientific Officer

    Steve has over 25 years of toxicology experience, including key roles as a drug development team representative for multiple therapeutic areas and in developing and implementing experimental and regulatory strategies to support development of promising preclinical drug candidates. In addition to cofounding XPD Holdings, Steve is a Partner and Chief Scientific Officer at INDS, Inc., an innovative nonclinical drug development consulting group.

  • Default avatar
    James R. Herman

    Jim has 25 years of nonclinical drug safety research and development experience, including tactical and strategic support of nonclinical development projects. Jim has significant experience in the regulatory toxicology field (US, EU, and Japan), and has contributed to over 100 IND and NDA submissions. In addition to cofounding XPD Holdings, Jim is a Partner and President at INDS, Inc., an innovative nonclinical drug development consulting group.

  • Default avatar
    Marc B. Bailie
    Chief Development Officer

    A founding member of XPD Holdings, Marc previously led the Safety Pharmacology Group at Pfizer, Ann Arbor. Marc was a key member of numerous Discovery and Development project teams at Pfizer and he has extensive experience evaluating the pharmacologic and toxicologic activity of drug candidates. Marc is also a founder and Chief Development Officer at INDS, Inc., an innovative drug development consulting group in Ann Arbor, MI.


  • Default avatar
    Dykema, Ann Arbor, MI
    Default avatar
    Stefforia, Petik and Associates, Ann Arbor, MI

Previous Investors

  • Default avatar
    Founding Members (7)